Impact on Glucocorticoids in COVID-19 Varies With CRP Levels
MONDAY, July 27, 2020 -- The impact of glucocorticoid treatment on patients with COVID-19 varies according to C-reactive protein (CRP) levels, according to a study published online July 22 in the Journal of Hospital Medicine.
Marla J. Keller, M.D., from Montefiore Medical Center and the Albert Einstein College of Medicine in Bronx, New York, and colleagues conducted an observational study involving 1,806 hospitalized COVID-19 patients; 140 were treated within 48 hours of admission with glucocorticoids.
The researchers observed no association between early use of glucocorticoids and mortality or mechanical ventilation. The risk for mortality or mechanical ventilation was significantly reduced in association with glucocorticoid treatment of patients with initial CRP ≥20 mg/dL (odds ratio, 0.23); the risk for mortality or mechanical ventilation was significantly increased in association with glucocorticoid treatment of patients with CRP <10 mg/dL (odds ratio, 2.64).
"Our findings suggest a role for CRP to identify patients who may benefit from glucocorticoid therapy, as well as those in whom it may be harmful," the authors write. "Additional studies to further elucidate the role of CRP in guiding glucocorticoid therapy and to predict clinical response are needed."
© 2021 HealthDay. All rights reserved.
Posted: July 2020
Further Support and Information on COVID-19
Read this next
FRIDAY, June 11, 2021 -- U.S. regulators have extended the expiration date on millions of Johnson & Johnson coronavirus vaccine doses by six weeks, the company announced...
FRIDAY, June 11, 2021 -- About 60 million doses of the Johnson & Johnson COVID-19 vaccine must be discarded due to possible contamination, the U.S. Food and Drug...
FRIDAY, June 11, 2021 -- Multisystem inflammatory syndrome in children (MIS-C) is a rare complication associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.